Author Details

Поддубная, Ирина Владимировна

Issue Section Title File
Vol 15, No 1 (2013) Articles CUP-syndrome: the present view of the problem (a review of literature)
Vol 15, No 2 (2013) Articles Prognostic value of p53 expression in patients with stage I breast cancer
Vol 15, No 2 (2013) Articles Toxicity of trabectedin-based combinations in the treatment of different malignant tumors
Vol 15, No 3 (2013) Articles Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii
Vol 15, No 3 (2013) Articles Rezul'taty «Epidemiologicheskoy programmy skrininga HER2-statusa u bol'nykh rakom molochnoy zhelezy» v Rossiyskoy Federatsii
Vol 15, No 4 (2013) Articles The efficiency of trabectedin in the monotherapy and combinations in the treatment of advanced ovarian cancer
Vol 15, No 4 (2013) Articles Bone mineral density in patient with breast cancer
Vol 16, No 1 (2014) Articles The Avastin application in clinical practice in patients with metastatic colorectal cancer: Second interim analysis of the observational AJAX program
Vol 16, No 4 (2014) Articles Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials)
Vol 17, No 1 (2015) Articles Breast cancer immunology: theory and prospects (review)
Vol 16, No 3 (2014) Articles Vulvar Langerhans cell histiocytosis: case report
Vol 17, No 1 (2015) Articles A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian
Vol 17, No 1 (2015) Articles Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience)
Vol 17, No 3 (2015) Articles The results of Epidemiological HER2 screening program in patients with breast cancer in 2014
Vol 17, No 3 (2015) Articles Clinical and prognostic significance of matrix metalloproteinase-7 and vascular endothelium growth factor in patients with ovarian cancer
Vol 17, No 3 (2015) Articles Current understanding of the role of insulin-like and vascular endothelial growth factors in development, prognosis and targeted therapy in patients with ovarian cancer
Vol 18, No 1 (2016) Articles Features of surgical treatment of patients with breast cancer receiving preoperative systemic therapy PDF
(Rus)
Vol 18, No 1 (2016) Articles Insulin-like growth factors in patients with ovarian tumors (results of own research) PDF
(Rus)
Vol 19, No 4 (2017) Articles Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0 PDF
(Rus)
Vol 19, No 3 (2017) Articles Dynamics of circulating tumor cells during neoadjuvant chemotherapy in patients with locally-advanced breast cancer PDF
(Rus)
Vol 20, No 1 (2018) Articles Taxanes induced peripheral neuropathy: mechanism of development and pharmacogenetic factors PDF
(Rus)
Vol 20, No 3 (2018) Articles The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer PDF
(Rus)
Vol 20, No 4 (2018) Articles Quality control of immunohistochemical analyzes in Russia: yesterday, today, tomorrow PDF
(Rus)
Vol 20, No 4 (2018) Articles Bendamustine in the treatment of B-cell non-Hodgkin lymphoma PDF
(Rus)
Vol 21, No 2 (2019) Articles Successful experience of combined immunochemotherapy at refractory course of primary cutaneous peripheral T-cell lymphoma, unspecified PDF
(Rus)
Vol 21, No 1 (2019) Articles Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports PDF
(Rus)
Vol 21, No 1 (2019) Articles The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review) PDF
(Rus)
Vol 21, No 4 (2019) CLINICAL ONCOLOGY The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution PDF
(Rus)
Vol 22, No 1 (2020) CLINICAL ONCOLOGY Solitary (extramedullary) plasmocytoma. Clinical recommendations PDF
(Rus)
Vol 22, No 1 (2020) CLINICAL ONCOLOGY ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution PDF
(Rus)
Vol 22, No 1 (2020) CLINICAL ONCOLOGY Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer PDF
(Rus)
Vol 22, No 2 (2020) Guidelines Hodgkin's lymphoma PDF
(Rus)
Vol 22, No 2 (2020) Guidelines Follicular lymphoma PDF
(Rus)
Vol 22, No 2 (2020) Conference Proceedings Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic PDF
(Rus)
Vol 22, No 2 (2020) Original Article Maintenance oncohematological patients and new coronavirus infection: experience of the City Clinical Hospital №52 PDF
(Rus)
Vol 22, No 2 (2020) Conference Proceedings New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas PDF
(Rus)
Vol 22, No 2 (2020) Review Accompanying therapy in oncohematological patients with secondary immunodeficiency PDF
(Rus)
Vol 22, No 2 (2020) Best Practice Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience PDF
(Rus) PDF
(Eng)
Vol 22, No 2 (2020) Original Article First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY Multiple myeloma PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy PDF
(Rus)
Vol 23, No 1 (2021) CLINICAL ONCOLOGY Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas PDF
(Rus)
Vol 23, No 2 (2021) CLINICAL ONCOLOGY Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization PDF
(Rus)
Vol 23, No 3 (2021) CLINICAL ONCOLOGY Extrapulmonary small cell carcinoma. Literature review PDF
(Rus)
Vol 23, No 2 (2021) CLINICAL ONCOLOGY The use of erythropoietins in oncology PDF
(Rus)
Vol 23, No 4 (2021) CLINICAL ONCOLOGY Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III PDF
(Rus)
Vol 24, No 1 (2022) CLINICAL ONCOLOGY Immuno-morphological characteristics of bone marrow in patients with ovarian cancer PDF
(Rus)
Vol 24, No 1 (2022) CLINICAL ONCOLOGY Therapy of lymphoproliferative diseases in the era of COVID-19: challenges and solutions PDF
(Rus)
Vol 24, No 1 (2022) CLINICAL ONCOLOGY From the editor-in-chief of the journal "Modern Oncology" Academician of the Russian Academy of Sciences I.V. Poddubnaya PDF
(Rus)
Vol 24, No 1 (2022) CLINICAL ONCOLOGY Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study PDF
(Rus)
Vol 24, No 3 (2022) CLINICAL ONCOLOGY Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study PDF
(Rus)
Vol 24, No 2 (2022) CLINICAL ONCOLOGY Risk of discrimination against Russian citizens in providing medical care abroad as a health care trend PDF
(Rus)
Vol 24, No 3 (2022) CLINICAL ONCOLOGY The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study PDF
(Rus)
Vol 24, No 3 (2022) CLINICAL ONCOLOGY Genetic markers associated with resistance to radioiodine therapy in thyroid cancer patients: Prospective cohort study PDF
(Rus)
Vol 25, No 1 (2023) CLINICAL ONCOLOGY Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study PDF
(Rus)
Vol 25, No 2 (2023) CLINICAL ONCOLOGY Heterogeneous diffuse large B-cell lymphoma: accurate diagnosis as a key to successful therapy. A review PDF
(Rus)
Vol 25, No 2 (2023) CLINICAL ONCOLOGY Challenges and perspectives of first-line therapy in patients with diffuse B-cell lymphoma: A review PDF
(Rus)
Vol 25, No 2 (2023) CLINICAL ONCOLOGY Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study PDF
(Rus)
Vol 25, No 3 (2023) History of medicine Memorial lecture to the 100th anniversary of the birth of Professor Yu.I. Lorie PDF
(Rus)
Vol 25, No 3 (2023) CLINICAL ONCOLOGY Diffuse large B-cell lymphoma: strokes to the epidemiological portrait. A review PDF
(Rus)
Vol 25, No 3 (2023) CLINICAL ONCOLOGY An interdisciplinary approach to the management of oncohematological patients with immunodeficiency: clinical cases. A review PDF
(Rus)
Vol 25, No 4 (2023) CLINICAL ONCOLOGY Can bispecific antibodies change the paradigm and goals of therapy for patients with relapsed non-Hodgkin lymphomas? PDF
(Rus)
Vol 25, No 4 (2023) CLINICAL ONCOLOGY Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study PDF
(Rus)
Vol 26, No 2 (2024) Articles Immunohistochemical factors of prognosis of immunotherapy for metastatic melanoma: А prospective and retrospective study PDF
(Rus)
Vol 26, No 3 (2024) Articles Role of immunohistochemical prognostic factors in various types of immunotherapy for metastatic melanoma: A retro-prospective study PDF
(Rus)
Vol 26, No 3 (2024) Articles Clinical significance of PET/CT in the diagnosis of primary adrenal malignancies PDF
(Rus)
Vol 26, No 4 (2024) Articles Peritoneal lymphomatosis as the only manifestation of diffuse B-cell large cell lymphoma: A clinical case PDF
(Rus)
Vol 27, No 1 (2025) Articles Efficacy and safety of immunotherapy for metastatic renal cell carcinoma: A retrospective study PDF
(Rus)

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».